Is precision psychiatry possible?
Anyone who has taken a psychiatric medication knows that the status quo in prescribing is a trial and error approach, with patients often cycling through an array of drugs to find the one t
Emergence of ADCs as the “hot, new technology”
The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting the
Endeavor raises $132.5m for fibrosis, cancer drugs
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
Alzheimer’s drug Leqembi moves forward, still in low gear
Biogen has given an update on the rollout of its Eisai-partnered Alzheimer’s disease therapy Leqembi alongside its first-quarter results, showing that while the drug’s tak
Roche says it has shed 20% of NMEs from its pipeline
Roche chief executive Thomas Schinecker said today that one in five of the pharma division’s pipel
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
FT US PHARMA AND BIOTECH SUMMIT
2024 is a pivotal year for the US healthcare sector.
9th Microbiome Movement Drug Development Summit
The Home of Accelerating Microbial-Based Drug Development
The PM Society – Giving Back
The PM Society is a not-for-profit organisation with 40 years of Giving Back.
5th Optimizing Hybrid Clinical Trials Summit
The 5th Optimizing Hybrid Clinical Trials Summit (September 11-12, 2024 | Boston, MA) is uniting stakeholders in Clinical Operations, Innovation, Procurement and Digital Health and
2nd RNA Assay Development Screening Summit
This August, the 2nd RNA Assay Development & Screening Summit returns to Boston as the first and only industry dedicated event on developing sensitive, and reproducible assay and screening meth